Nearly half of lymphoma patients treated with Gilead Sciences Inc's Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday.
from Reuters: Science News https://ift.tt/2Lx1vo4
0 comments:
Post a Comment